NCT03525834 2021-09-09
Safety and Efficacy of Everolimus (Afinitor®) in Chinese Adult Patients With Angiomyolipoma Associated With Tuberous Sclerosis Complex.
Novartis
Phase 4 Completed
Clinical Trials
12 trialsNCT02451696 2021-09-01
A Pilot Study To Evaluate The Effects of Everolimus on Brain mTOR Activity and Cortical Hyperexcitability in TSC and FCD
NYU Langone Health
Phase 2 Completed
NCT01929642 2021-03-29
RAPT
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
Phase 2 Completed
NCT02201212 2020-09-16
Everolimus for Cancer With TSC1 or TSC2 Mutation
Dana-Farber Cancer Institute
Phase 2 Completed
NCT02061397 2020-08-25
SOS
University of Pennsylvania
Phase 1/2 Completed
NCT01289912 2018-01-25
TSC
Boston Children's Hospital
Phase 2 Completed
NCT01070316 2017-03-13
Everolimus (RAD001) Therapy for Epilepsy in Patients With Tuberous Sclerosis Complex (TSC)
Children's Hospital Medical Center, Cincinnati
Phase 1/2 Completed
NCT00790400 2017-02-17
EXIST-2
Novartis
Phase 3 Completed
NCT00789828 2016-02-03
EXIST-1
Novartis
Phase 3 Completed
NCT00411619 2014-10-20
Everolimus (RAD001) Therapy of Giant Cell Astrocytoma in Patients With Tuberous Sclerosis Complex
Children's Hospital Medical Center, Cincinnati
Phase 1/2 Completed
NCT00457964 2013-09-25
RAD001 Therapy of Angiomyolipomata in Patients With TS Complex and Sporadic LAM
Children's Hospital Medical Center, Cincinnati
Phase 1/2 Completed
NCT00792766 2013-09-18
Long Term Follow Up for RAD001 Therapy of Angiomyolipomata in Patients With Tuberous Sclerosis (TSC) and Sporadic Lymphangioleiomyomatosis (LAM)
Children's Hospital Medical Center, Cincinnati
Phase 1/2 Completed